Synaffix’s glycan-based antibody–drug conjugate technology is experiencing strong demand, based on its potential to improve safety and efficacy of cancer therapies without genetic engineering.

Antibody–drug conjugates (ADCs) combine the targeting ability of monoclonal antibodies with the cell-killing effects of potent cytotoxic drugs. Over the past decade, the approach has moved from ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.